MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cancers18152522

Медицинская библиотека · Cancers · 2026

Reduced-Dose Regorafenib for Recurrent Glioblastoma: A Safety and Outcome Analysis.

Rizzaro Massimiliano Domenico, Fanizzi Claudia, Fiore Giorgio, Remore Luigi Gianmaria, Vecchio Guido Del, Scagliotti Elena, Pratelli Giovanni, Borsa Stefano, Navone Stefania Elena, Bertorelli Ilaria, Sironi Luca Enrico, Roda Gabriella, Marfia Giovanni, Caroli Manuela, Locatelli Marco

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND/

OBJECTIVES

Recurrent glioblastoma has a poor prognosis and no universally accepted standard of care. Regorafenib has been investigated in this setting, but its use may be limited by treatment-related toxicity. This study evaluated the feasibility, safety, and clinical outcomes of reduced-dose regorafenib in patients with recurrent IDH-wildtype glioblastoma.

METHODS

We retrospectively analyzed 21 patients with recurrent IDH-wildtype glioblastoma (WHO 2021) treated at a single center after progression according to the Stupp protocol. Regorafenib was started at 80 mg/day on the standard 3-weeks-on/1-week-off schedule. We assessed overall survival from diagnosis (OS1) and from first progression (OS2), progression-free survival from diagnosis (PFS1) and from first progression (PFS2), treatment exposure, dose modifications, and treatment-related adverse events (CTCAE v5.0).

RESULTS

Median PFS2 was 5 months (95% CI, 3-8), median OS2 was 6 months (95% CI, 5-10), and median OS1 was 21 months (95% CI, 15-27). No grade ≥ 3 adverse events occurred, and no patient discontinued treatment permanently because of toxicity.

CONCLUSIONS

In this retrospective single-center cohort, reduced-dose regorafenib was feasible and well tolerated in selected patients. These descriptive, hypothesis-generating findings warrant prospective studies to define the role of individualized regorafenib dosing in recurrent glioblastoma.

Для цитирования: Rizzaro Massimiliano Domenico, Fanizzi Claudia, Fiore Giorgio, Remore Luigi Gianmaria, Vecchio Guido Del, Scagliotti Elena, Pratelli Giovanni, Borsa Stefano, Navone Stefania Elena, Bertorelli Ilaria, Sironi Luca Enrico, Roda Gabriella, Marfia Giovanni, Caroli Manuela, Locatelli Marco. Reduced-Dose Regorafenib for Recurrent Glioblastoma: A Safety and Outcome Analysis.. Cancers. 2026. DOI: 10.3390/cancers18152522.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.